Phase 1 & 2 full results for Lorlatinib

As of Oct. 16, 2017 Pfizer presented a Press release associated with a presentation at IASLC on Phase 2 results for 275 patients.

All following are for ALK+ patients except where Ros1 is indicated

Treatment Naive:  ORR 90%; IC-ORR 75%

Prior treatment with Crizotinib: ORR 69%; IC-ORR 68%

Prior treatment with ALK Inhibitor other than Crizotinib: ORR 33%; IC-ORR 42%

Prior treatment with 2+ ALK Inhibitors: ORR 39%; IC-ORR 48%

ROS1 + regardless of prior treatments: ORR 36%; IC-ORR 56%

ORR = Objective Response Rate

IC-ORR = Intracranial ORR

for more details from press release see: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_full_results_from_phase_2_study_of_next_generation_investigational_alk_inhibitor_lorlatinib_in_alk_positive_and_ros1_positive_advanced_non_small_cell_lung_cancer

 

As of Dec. 2017 an article was published of Phase 1 results for 54 patients

For all 41 ALK+ patients the ORR was 46%

For 26 ALK+ patients that received 2+ ALK Inhibitors the ORR was 42%

For 12 ROS1 +patients the ORR was 50%

For published article see also https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(17)30680-0.pdf

This entry was posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects. Bookmark the permalink.

Leave a Reply